| Interest in Lpath Inc. (LPTN) has been rising along with share prices. The stock closed nearly 7% higher on Thursday and capped off another positive session. The emerging biotech had seen considerable interest from biotech investors and speculators before a temporary halt in the company's iSONEP trial was announced in January due to no fault of either Lpath or their clinical partner Pfizer Pharmaceuticals. The FDA had targeted Formatech, Inc., a vendor/contractor which was providing fill/finish servi...continued LPTN vegf angiogenesis pharmaceuticals |
Thursday, March 1, 2012
Keeping an eye on Lpath as shares look to build momentum
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment